Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 May;52(5):683-688.
doi: 10.1038/bmt.2016.348. Epub 2017 Jan 16.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

L Castagna  1 , S Bramanti  1 , R Devillier  2 , B Sarina  1 , R Crocchiolo  1 , S Furst  2 , J El-Cheikh  2 , A Granata  2 , C Faucher  2 , S Harbi  2 , L Morabito  1 , J Mariotti  1 , S Puvinathan  3 , P J Weiller  2 , C Chabannon  4   5   6 , D Mokart  7 , C Carlo-Stella  1   8 , R Bouabdallah  2 , A Santoro  1   9 , D Blaise  2   5   6
Affiliations
Multicenter Study

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

L Castagna et al. Bone Marrow Transplant. 2017 May.

Erratum in

  • Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D. Castagna L, et al. Bone Marrow Transplant. 2017 May;52(5):797. doi: 10.1038/bmt.2017.26. Bone Marrow Transplant. 2017. PMID: 28465624 No abstract available.

Abstract

We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.

PubMed Disclaimer

Publication types

Substances